Jaguar Health advances extension phase of pivotal oral crofelemer trial in pediatric MVID patients

• Jaguar Health highlighted ongoing development of a liquid crofelemer formulation for rare pediatric intestinal-failure disorders, targeting a potential mid-2027 NDA filing.
• Earlier proof-of-concept results were already presented at NASPGHAN 2025, indicating reduced reliance on parenteral support in initial MVID and SBS-IF patients.
• New data are set for future presentation via two late-breaking abstracts at ESPGHAN, covering investigator-initiated and expanded-access use in pediatric patients.
• The company is running an extension phase of its pivotal MVID study, with an active-treatment-only continuation intended to support the planned regulatory submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605281000ACCESSWRNAPR_____1171349) on May 28, 2026, and is solely responsible for the information contained therein.